Form D · Pharmaceuticals

Kereos, Inc

St. Louis, MO · CIK 0001329246

Offering snapshot reported Jan 12, 2012 · SEC filing

Reported sold
$1.13M
Offering amount: $1.13M
Investors reported
9
Form D · investor count
Minimum accepted
$2K
Reported outside-investor minimum
First sale
Sep 23, 2011
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 12, 2012Initial$1,127,730No comparison9SEC filing
May 6, 2010Initial$5,675,098No comparison13SEC filing
Jun 26, 2009Initial$887,126No comparison13SEC filing
Jul 1, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Jun 1, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-171638

Source: Form D, filed Jan 12, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Phillip M. Buckler Executive
Gregory R. Johnson, Ph. D. Director
Gregory R. Johnson, Ph.D. Director
Michael D. Loberg, Ph. D. Director
Michael Loberg, Ph.D. Director
John Rice, Ph. D. Director
John Rice, Ph.D. Director
Fred Schwartzer Director
Fred Schwarzer Director
Fred A. Schwarzer, J.D. Director
Stephen Snowdy Director
Stephen Snowdy, Ph.D. Director
Gary Stevenson Director
Samuel A. Wickline, M.D. Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
4041 Forest Park Ave
St. Louis, MO, 63108